2025-11-05T12:36:08-06:00 2024-12-31 882730877 CHERRY BEKAERT ADVISORY LLC 702 NORTH SHORE DRIVE STE 100 JEFFERSONVILLE IN 47130 990 2024-01-01 851792143 A CURE FOR ROBERT INC ACUR 5028026337 508 TIFFANY LN LOUISVILLE KY 40207 ROBERT B VICE JR PRESIDENT 5028026337 2025-11-03 1 1 MELANIE MCPEAK P01346034 8126703400 2024 2025-03-06 01:10:19Z ROBERT B VICE JR 508 TIFFANY LN LOUISVILLE KY 40207 821348 0 X N/A X 2020 KY THE ORGANIZATION IS WORKING TO FIND A CURE OR TREATMENT FOR MUCOPOLYSACCHARIDOSIS TYPE IVA ("MORQUIO") THROUGH FUNDRAISING AND GRANTING OF FUNDS TO VARIOUS RESEARCH INSTITUTIONS. 9 9 0 20 0 0 724000 757385 0 0 2341 29238 -33187 -50711 693154 735912 180000 357480 0 0 0 0 1490 4185 4185 16199 20435 197689 382100 495465 353812 1218573 1572385 0 0 1218573 1572385 THE ORGANIZATION IS WORKING TO FIND A CURE OR TREATMENT FOR MUCOPOLYSACCHARIDOSIS TYPE IVA ("MORQUIO") THROUGH FUNDRAISING AND GRANTING OF FUNDS TO VARIOUS RESEARCH INSTITUTIONS. 0 0 376584 357480 THE ORGANIZATION IS WORKING TO FIND A CURE OR TREATMENT FOR MUCOPOLYSACCHARIDOSIS TYPE IVA ("MORQUIO") THROUGH FUNDRAISING AND GRANTING OF FUNDS TO VARIOUS RESEARCH INSTITUTIONS.THIS DISEASE IS A RARE GENETIC DISEASE THAT PROHIBITS THE BODY FROM BREAKING DOWN CERTAIN SUGARS. IT IS SEVERELY PROGRESSIVE, AND THE EFFECTS OF THE DISEASE WILL GET SIGNIFICANTLY WORSE WITH TIME. THE DISEASE AFFECTS ABOUT 1 IN 200,000 PEOPLE, BUT THE EFFECTS ARE FELT IN COMMUNITIES THROUGH THE UNITED STATES AND WORLD. THERE IS ONE TREATMENT AVAILABLE- A SLOW WEEKLY INTRAVENOUS MEDICATION THAT IS DISRUPTIVE, EXPENSIVE, CAUSES ADVERSE REACTIONS (MANY CANNOT TAKE IT), AND WORSE, HAS BEEN PROVEN TO HAVE LIMITED EFFECTS. 376584 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 9 9 1 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 0 0 0 KY X DEANA PARADIS 5028026337 508 TIFFANY LN LOUISVILLE KY 40207 X ROBERT B VICE JR PRESIDENT 2.00 0.00 X X 0 0 0 HELEN K VICE VICE PRESIDENT 2.00 0.00 X X 0 0 0 DEANA PARADIS TREASURER 2.00 0.00 X X 0 0 0 LINDSEY FASH DIRECTOR 1.00 0.00 X 0 0 0 DR HEATHER GREENWOOD DIRECTOR 1.00 0.00 X 0 0 0 DR LINDSAY KROENER DIRECTOR 1.00 0.00 X 0 0 0 DR MATTHEW PRICE DIRECTOR (FROM 12/24) 1.00 0.00 X 0 0 0 DR AUDRA N RANKIN DIRECTOR 1.00 0.00 X 0 0 0 CHAD STRAUGHAN DIRECTOR 1.00 0.00 X 0 0 0 0 0 0 0 0 0 0 0 490275 267110 757385 29238 29238 34725 490275 85436 -50711 -50711 735912 0 0 -21473 357480 357480 4185 4185 19284 19104 180 1151 1151 382100 376584 1331 4185 416232 240806 802341 1331579 1218573 1572385 0 0 X 0 0 0 0 1218573 1572385 1218573 1572385 1218573 1572385 353812 0 X 0 0 0 X 500567 566306 724000 757385 2548258 500567 566306 724000 757385 2548258 190014 2358244 2341 29238 31579 1286 1286 2581123 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED ROOTING FOR ROBERT ANNUAL FUNDRAISE 525000 490275 34725 20085 7670 32414 25267 525000 490275 34725 20085 7670 32414 25267 85436 -50711 1 ST LOUIS UNIVERSITY 3450 LINDELL BLVD ST LOUIS MO 63103 430654872 501(C)(3) 150000 0 PROVIDE FUNDING FOR MEDICAL RESEARCH THE NEMOURS FOUNDATION 10140 CENTURION PARKWAY NORTH JACKSONVILLE FL 32256 590634433 501(C)(3) 167480 0 PROVIDE FUNDING TO HELP CHILDREN AND THEIR FAMILIES WITH MEDICAL CARE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 400 PARNASSUS AVE SAN FRANCISCO CA 94143 946036493 501(C)(3) 40000 0 PROVIDING FUNDING FOR EDUCATION AND RESEARCH 3 0 PART I, LINE 2: THE ORGANIZATION GRANTS MONEY TO ORGANIZATIONS VIA A GRANT AGREEMENT, WHICH REQUIRES PERIODIC REPORTING REQUIREMENTS AND HAS EVENTS OF DEFAULT ENUMERATED. A RESEARCH STUDY IS COMPLETED, AND CONCLUSIONS AND FACTS ARE PRESENTED TO A CURE FOR ROBERT, INC. FORM 990, PART VI, SECTION A, LINE 2 ROBERT B. VICE JR., PRESIDENT, AND HELEN K. VICE, VICE PRESIDENT, HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO OTHER COMMITTEES AT THIS TIME. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WILL BE PROVIDED TO ALL MEMBERS OF THE GOVERNING BODY PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C TO ENSURE THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH CHARITABLE PURPOSES AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE ITS TAX-EXEMPT STATUS, PERIODIC REVIEWS SHALL BE CONDUCTED OF DIRECTORS AND OFFICERS. THE PERIODIC REVIEWS SHALL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS:(A) WHETHER COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND THE RESULT OF ARM'S LENGTH BARGAINING.(B) WHETHER PARTNERSHIPS, JOINT VENTURES, AND ARRANGEMENTS WITH MANAGEMENT ORGANIZATIONS CONFORM TO THE FOUNDATION'S WRITTEN POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE INVESTMENT OR PAYMENTS FOR GOODS AND SERVICES, FURTHER CHARITABLE PURPOSES AND DO NOT RESULT IN INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT, OR IN AN EXCESS BENEFIT TRANSACTION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.